Source study found
Story checked
Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs (opens in a new tab)
news-medical.net · 2026-04-09
Short answer
Needs reviewStudy found.
We found the study, but the claim check did not finish.
Share this check
The story
Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs
news-medical.net · 2026-04-09
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We found the study behind this story.
We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.
Open claim evidenceThe source study
Genetic predictors of GLP1 receptor agonist weight loss and side effects
Evidence layer
Claim by claim
The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedThis large genetic study suggests inherited differences in drug-target genes may shape both weight-loss success and the risk of nausea and vomiting on GLP-1 drugs.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 2 of 5Not checkedIn a recent study published in Nature, researchers conducted a large-scale genome-wide association study (GWAS) of 27,885 participants to investigate the genetic basis of variability in GLP-1 receptor agonist response.View evidenceHide evidence
As stated27,885 participants
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 3 of 5Not checkedThe study identified a missense variant in GLP1R associated with enhanced weight-loss efficacy, with each copy of the effect allele predicting an additional 0.76 kg of weight loss in the sample cohort.View evidenceHide evidence
As stated0.76 kg additional weight loss per effect allele
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 4 of 5Not checkedGenetic variation in GLP1R and GIPR was linked to medication-induced nausea and vomiting, with the GIPR association seen only in patients using tirzepatide.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 5 of 5Not checkedThe article says the findings suggest common genetic variation in drug-target genes directly contributes to patient response and adverse-event risk, and could eventually help stratify patients for efficacy and side effects.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Genetic predictors of GLP1 receptor agonist weight loss and side effects
Nature · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, PubMed, Europe PMC · 16 candidate papers
Genetic predictors of GLP1 receptor agonist weight loss and side effects
Nature · 2026 · Crossref
The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists.
Diabetes Care · 2026 · PubMed
A278 GLP-1 Receptor Agonist Use for Weight Loss Management After Bariatric Surgery
Surgery for Obesity and Related Diseases · 2023 · Crossref
Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity.
Life (Basel, Switzerland) · 2026 · PubMed, Europe PMC
Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence.
Hormones (Athens, Greece) · 2026 · PubMed
Daily GLP-1 receptor agonist pill leads to ‘significant’ weight loss
Pharmaceutical Journal · 2025 · Crossref
And 10 more candidates considered.